Reply to: "Seladelpar in patients with primary biliary cholangitis: Need for a closer look!"
- PMID: 35977610
- DOI: 10.1016/j.jhep.2022.07.024
Reply to: "Seladelpar in patients with primary biliary cholangitis: Need for a closer look!"
Keywords: Clinical study; Primary biliary cholangitis; Seladelpar.
Conflict of interest statement
Conflict of interest Christopher Bowlus has received grants from Arena Pharmaceuticals, Cara Therapeutics, Genfit, Genkyotex, and Novartis and grants and personal fees from CymaBay Therapeutics, Eli Lilly, Gilead, GlaxoSmithKline, and Intercept. Cynthia Levy has received grants from Genkyotex, Gilead, High Tide, Intercept, Novartis, and Zydus and grants and personal fees from Cara Therapeutics, CymaBay Therapeutics, Genfit, and GlaxoSmithKline. Gideon M. Hirschfield has received personal fees from CymaBay Therapeutics, Genfit, GlaxoSmithKline, HighTide, Intercept Pharma, Mirum, and Pliant. Please refer to the accompanying ICMJE disclosure forms for further details.
Comment on
-
A phase II, randomized, open-label, 52-week study of seladelpar in patients with primary biliary cholangitis.J Hepatol. 2022 Aug;77(2):353-364. doi: 10.1016/j.jhep.2022.02.033. Epub 2022 Mar 30. J Hepatol. 2022. PMID: 35367282 Clinical Trial.
-
Seladelpar in patients with primary biliary cholangitis: Need for a closer look!J Hepatol. 2022 Nov;77(5):1451. doi: 10.1016/j.jhep.2022.04.039. Epub 2022 May 17. J Hepatol. 2022. PMID: 35594993 No abstract available.
Similar articles
-
Seladelpar in patients with primary biliary cholangitis: Need for a closer look!J Hepatol. 2022 Nov;77(5):1451. doi: 10.1016/j.jhep.2022.04.039. Epub 2022 May 17. J Hepatol. 2022. PMID: 35594993 No abstract available.
-
Seladelpar: an investigational drug for the treatment of early-stage primary biliary cholangitis (PBC).Expert Opin Investig Drugs. 2022 Oct;31(10):1101-1107. doi: 10.1080/13543784.2022.2130750. Epub 2022 Oct 8. Expert Opin Investig Drugs. 2022. PMID: 36194037
-
Seladelpar in primary biliary cholangitis.Nat Rev Gastroenterol Hepatol. 2024 May;21(5):300. doi: 10.1038/s41575-024-00922-3. Nat Rev Gastroenterol Hepatol. 2024. PMID: 38519788 No abstract available.
-
Recognizing primary biliary cirrhosis and primary sclerosing cholangitis.Am Fam Physician. 1996 Jan;53(1):195-200. Am Fam Physician. 1996. PMID: 8546046 Review.
-
Primary sclerosing cholangitis.Prog Liver Dis. 1986;8:557-80. Prog Liver Dis. 1986. PMID: 3520670 Review. No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources